Background-To evaluate outcomes after carotid artery stenting in larger real-world populations, the Food and Drug Administration mandated that companies conduct postmarketing surveillance (PMS) studies of approved stent systems. Whether PMS studies are representative of carotid artery stenting in routine clinical practice has not been established. Methods and Results-Within the National Cardiovascular Database Registry-Carotid Artery Revascularization and Endarterectomy (NCDR CARE) Registry, we compared patient and procedural characteristics, in-hospital outcomes, and subsequent all-cause mortality after carotid artery stenting in PMS study participants and nonparticipants. We conducted both crude and propensity score-adjusted comparisons for all outcomes between groups. Compared with nonparticipants, participants in PMS studies had lower rates of symptomatic carotid artery disease within the preceding 6 months, prior stroke, and acute evolving stroke at baseline. The PMS study participants had lower unadjusted rates of combined in-hospital death, stroke, or myocardial infarction (2.3% versus 4.1%; PϽ0.001), driven by lower rates of stroke (1.7% versus 2.7%; Pϭ0.005) and death (0.3% versus 1.4%; PϽ0.001). Differences in survival persisted after propensity score adjustment (odds ratio, 0.44; 95% confidence interval, 0.21 to 0.95; Pϭ0.04 for in-hospital mortality; and hazard ratio, 0.80; 95% confidence interval, 0.66 to 0.97; Pϭ0.02 for 2-year mortality). Baseline differences in neurological history explained the largest proportion of the difference in outcomes between groups. 
W ith the explosion of new therapeutic interventions, pharmaceutical and device companies have begun designing very focused randomized trials to maximize the probability of successfully demonstrating the benefit of novel interventions over standard therapy. Accordingly, the Food and Drug Administration has increasingly granted approval to new treatments conditioned on requirements that manufacturers conduct postmarketing surveillance (PMS) studies of their treatments, with the goal of evaluating their performance under more real-world circumstances. 1, 2 However, although results from PMS studies have often been cast as representing those that might be seen in everyday practice, [1] [2] [3] explicit demonstration that PMS study patients are truly representative of the broader population undergoing treatment with approved devices and medications in the community is lacking.
and Drug Administration mandated as a condition of their approval that manufacturers of carotid stents conduct PMS studies to determine outcomes after CAS outside the clinical trial setting. 10, 11 However, the size and conduct of these PMS studies of CAS are not uniform, and these studies can vary in terms of patient numbers, duration of follow-up, and amount and type of information collected. To address whether patients undergoing CAS within PMS studies are representative of the broader population undergoing CAS in the community, we compared clinical characteristics and outcomes of CAS patients participating and not participating in PMS studies as part of the National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy (NCDR CARE) Registry.
Methods
The CARE Registry is a comprehensive national registry of patients undergoing both CAS and carotid endarterectomy. 12 The registry was established in 2008 through a multidisciplinary collaboration with the purpose of serving as a national surveillance system of carotid endarterectomy and CAS and facilitating efforts to improve the quality and safety of managing carotid artery disease. The CARE Registry is a voluntary registry that, at the time of this analysis, includes Ͼ15 483 carotid revascularization procedures (8714 CAS, 6769 carotid endarterectomy) performed at 171 hospitals in the United States. All adult patients Ն18 years of age who undergo CAS or carotid endarterectomy at any of these institutions are included in the registry with no other exclusions. Although reasonable safeguards are taken by the registry to protect patient privacy as stipulated under the Health Insurance Portability and Accountability Act of 1996, participation in the registry by hospitals does not require Institutional Review Board review or informed consent of patients. Sites are expected to submit data on all qualifying revascularization procedures to the registry. The registry is funded by the American College of Cardiology Foundation without other external funding.
Study Population
Within this registry, we identified patients undergoing CAS between January 1, 2005, and October 31, 2009. Patients enrolled in a CAS preapproval clinical trial, which typically has stringent inclusion and exclusion criteria, were excluded from the analysis. Previous studies have suggested different outcomes at hospitals that participate in preapproval clinical trials compared with those that do not. 13, 14 We therefore conducted sensitivity analyses in which patients undergoing CAS at hospitals who did not enroll any patients in preapproval clinical trials were excluded. These analyses showed similar results; therefore, these hospitals were included in the primary analysis.
Patient Characteristics and Outcomes
A primary goal of our research was to compare characteristics of participants and nonparticipants of PMS studies. Data collection in the CARE Registry is performed with a Web-based tool that captures demographic information, patient clinical history and risk factors, procedural characteristics, medications, and procedure-related adverse events. The data collection form includes a variable in which patients can be designated as either participants or nonparticipants in a clinical trial. If patients are participants in a clinical trial, sites additionally submit whether the trial was a PMS, a premarket approval or investigational device exemption study, or other type of trial. PMS studies are defined in the registry data dictionary in accordance with the Food and Drug Administration definition as those studies established to detect unforeseen adverse events in devices intended to be implanted in the human body for Ͼ1 year, devices for which failure would be likely to have serious adverse health consequences, or devices intended to be used to support or sustain life.
Patient characteristics and outcomes are ascertained by sites using uniform data definitions. The complete set of CARE Registry variables and definitions can be found at http://www.ncdr.com/ WebNCDR/CAROTIDSTENT/ELEMENTS.ASPX. Prior neurological event was defined as any transient ischemic attack, ischemic stroke, or intracranial hemorrhage. Symptomatic status of the target lesion within the previous 6 months was ascertained, defined as transient ischemic attack, nondisabling stroke with modified Rankin Scale score of Ͻ3, or transient monocular blindness. Acute evolving stroke was defined as any sudden development of neurological deficits attributable to cerebral ischemia and/or infarction, with onset of symptoms occurring within the prior 3 days and ongoing at the time of procedure and symptoms progressively worsening.
Our primary end points included in-hospital all-cause death, myocardial infarction, or stroke and the composite of these. In addition, postdischarge all-cause mortality was ascertained from the Social Security Death Index for up to 2 years of follow-up.
Statistical Analyses
We compared patient and procedural characteristics and in-hospital outcomes for PMS study participants and nonparticipants using t tests for continuous variables or 2 tests for categorical variables. Unadjusted all-cause mortality was compared by use of the log-rank test. To determine whether differences in outcomes between study participants and nonparticipants could be accounted for by patient and procedural characteristics, we developed a series of nested propensity score models predicting inclusion in a PMS study conditioned on up to 41 covariates (see Table I in the online-only Data Supplement) using logistic regression. Beginning with an unadjusted model, we added variables sequentially in the following groups: (1) sociodemographic characteristics, (2) noncardiac and nonneurovascular comorbidities, (3) prior cardiovascular disease, (4) neurological histories, (5) procedural characteristics, and (6) hospital characteristics, leading to 6 separate propensity score models. At each level, we calculated standardized differences to assess balance after propensity score adjustment. 15 Because 2 variables (symptomatic target lesion and prior neurological event) had standardized differences of Ͼ10%, we adjusted for these variables in addition to the propensity score for the final model (Table II in the online-only Data Supplement). We then examined the association between PMS study participation and outcomes using logistic regression or Cox proportional-hazards models, as appropriate, sequentially adjusting for the propensity scores derived from each of the 6 models. Propensity scores were included in all models as linear terms. To additionally assess for the adequacy of propensity score adjustment, a sensitivity analysis using 1-to-many matching based on propensity score from the final model was also performed and showed results similar to the primary analysis (data not shown). 16 In the final model that included hospital variables, we used hierarchical generalized linear models assuming hospital random effects while modeling hospital characteristics as fixed effects. Hospital characteristics included teaching status, geographic region, profit type, urban versus rural, and public versus nonpublic.
To quantify the extent to which the association between PMS study participation and mortality was attributable to these factors, we calculated the relative attenuation of the coefficients derived from these sequential models, computed as [
, where ␤ i represents the coefficient associated with PMS study participation in the unadjusted model and ␤ j represents the adjusted coefficient in the subsequent model adjusted for propensity score. 17, 18 To eliminate potential confounding by temporal trends in care, a time variable was included in all propensity models. All statistical analyses were performed by the Saint Luke's Mid America Heart Institute Department of Biostatistics using SAS version 9.2 (SAS Institute, Cary, NC).
Results
Between January 1, 2005, and October 31, 2009, there were 7737 patients who underwent CAS and were enrolled in the CARE registry. We excluded 622 patients enrolled in a premarket study or in whom information about clinical study participation was unavailable. Of the remaining 7115 patients, 3689 (51.8%) were participants in a PMS study. Enrollment in PMS studies progressively increased from Ϸ20% at the end of 2005 to Ͼ60% in 2009 and was broadly distributed among CARE registry sites (Figures I and II in the online-only Data Supplement).
Patients participating in PMS studies differed from nonparticipants across a number of characteristics, most significantly in their neurological histories (Table 1 ). PMS study participants had significantly lower rates of prior stroke (13.7% versus 19.2%; PϽ0.001), symptomatic target lesions (31.5% versus 58.2%; PϽ0.001), and acute evolving stroke (1.0% versus 3.9%; PϽ0.001). A comparison of procedural characteristics showed that PMS study participants had significantly higher rates of attempted and successful embolic protection device deployment, among other differences.
Unadjusted Outcomes
PMS study participants had lower rates of composite inhospital death, stroke, or myocardial infarction compared with nonparticipants (4.1% versus 5.6%; Pϭ0.004), driven by a lower rate of in-hospital death (0.3% versus 1.4%; PϽ0.001; Table 2 ). Cumulative all-cause mortality was significantly lower in PMS study participants compared with nonparticipants at 2 years PϽ0.001; Figure) .
Propensity Score-Adjusted Outcomes and Percent Difference Explained
After propensity score adjustment based on assessed variables (patient, procedural, and hospital), there was no significant difference in the combined end point of in-hospital death, myocardial infarction, or stroke between PMS study participants and nonparticipants (odds ratio, 0.76; 95% confidence interval, 0.55 to 1.05; Pϭ0.10). However, in-hospital and subsequent all-cause mortality continued to be lower in study participants compared with nonparticipants (odds ratio, 0.44; 95% confidence interval, 0.21 to 0.95; Pϭ0.04 for in-hospital mortality; and hazard ratio, 0.80; 95% confidence interval, 0.66 to 0.97; Pϭ0.02 for 2-year mortality). For each end point, differences in baseline neurological history were the primary reason accounting for differences between PMS participant and nonparticipant outcomes, explaining 32.6% of the difference in the combined in-hospital death, myocardial infarction, or stroke; 30.2% of the difference in in-hospital death; and 16.0% of the difference in death for up to 2 years compared with the prior propensity score-adjusted models (Table 3) . Hospital characteristics (teaching status, geographic region, profit type, urban versus rural, and public versus nonpublic status) did not account for any of the observed difference in outcomes between PMS participants and nonparticipants. A substantial portion of the observed differences in outcomes between groups was not accounted for by any of the assessed variables (45.8% for the combined end point, 48.6% for in-hospital death, and 75.1% for death in follow-up to 2 years).
Discussion
Using data from the NCDR CARE registry, we observed significant differences in the clinical characteristics of patients undergoing CAS as part of PMS studies compared with those not participating in such studies. In addition, both in-hospital mortality and long-term mortality were higher in nonparticipating patients compared with participating patients.
PMS studies are often mandated by the Food and Drug Administration as part of the device approval process to examine rare events and to evaluate device performance outside the strict inclusion and exclusion criteria of clinical trials. Most large PMS studies enrolling patients during the period that we examined had liberalized criteria for enrollment with the intent to enroll a broader population compared with premarket trials. Although some studies are currently ongoing, published results from prior PMS studies have shown low rates of adverse events after CAS, similar to results achieved in pivotal randomized clinical trials. 10, 11 However, there are no uniform or standard criteria for these PMS studies, and they can vary substantially in design.
Although concerns regarding the generalizability of premarket randomized clinical trials have been raised previously for medications and for devices and procedures used to treat various diseases, including carotid artery disease, the presumption of PMS studies is that they do not necessarily suffer this limitation. 13,19 -25 Our data challenge this assumption and suggest that PMS study results may not be representative of the larger population of patients being treated with these devices. Within the CARE registry, patients participating in PMS studies were significantly different in many clinical and procedural characteristics compared with those not participating, and had lower rates of in-hospital and long-term mortality. To the best of our knowledge, direct comparisons of patient characteristics and outcomes between PMS study and nonstudy populations have not been performed previously for CAS or other cardiovascular devices.
Differences in baseline neurological history were the primary factors that accounted for the differences in in-hospital and long-term outcomes after carotid stenting between PMS study participants and nonparticipants. Why these differences existed is not clear. Although acute evolving stroke may have precluded some of these patients from participating in PMS studies, it was seen in only 2.4% of the overall patients in the CARE Registry. It is possible, however, that nonparticipants, who more often had recent symptomatic events and worse National Institutes of Health Stroke Scale scores, may have been able less often to give the informed consent necessary for PMS study participation. The adjustment for hospitallevel variables in a hierarchical model suggested that hospital-level characteristics could not account for the observed differences in outcomes between the groups. Differences in quality of care at hospitals that participate in clinical studies compared with those that do not have been described previously. 13 However, we observed similar results after excluding patients who underwent CAS at hospitals that did not enroll any PMS study patients.
Reasons for differences in outcomes between study participants and nonparticipants after propensity score adjustment are likely multifactorial. Although PMS studies enrolling patients during the study period had broad inclusion and limited exclusion criteria (see Table III in the online-only Data Supplement), these criteria still may have accounted for the observed differences in patient populations. In addition, differences in reimbursable indications for CAS depending on whether patients were participants or nonparticipants in PMS studies implemented by the Centers for Medicare and Medicaid Services may have led to systematic differences in the clinical histories of these patient groups. 26 Although some of these factors, including patient comorbid disease and symptomatic status, would have been accounted for by the propensity score adjustment, other factors may not have been adequately accounted for in the models. It is possible that patients undergoing procedures outside PMS studies may more often have had off-label indications for procedures, which may have been associated with worse outcomes, as has been seen for other devices. 27, 28 Importantly, in contrast to the CARE Registry, involvement in PMS typically requires signed informed consent of the study participant. In a study of the Registry of the Canadian Stroke Network, 
Figure.
Unadjusted cumulative all-cause mortality for postmarketing study participants (black) and nonparticipants (gray). Log-rank PϽ0.001.
Tu et al 29 found that the requirement for informed consent led to significant selection biases, adversely affecting the representativeness of the population included in the registry. Such selection bias may exist for PMS studies of CAS because the ability, motivation, and willingness to participate in a PMS study may result in the selection of a healthier cohort of patients. Finally, it is possible that the patients undergoing CAS outside the PMS setting are higher risk, so a truly representative population would have results that were intermediate between those observed for the PMS and non-PMS populations. We believe our results have important implications. Because the results from PMS studies for carotid stenting may not be generalizable to larger, routine clinical practice settings, they may be insufficient for monitoring long-term community-based outcomes. These findings highlight the importance of inclusive nationwide clinical registries such as the CARE Registry to fulfill these important roles for the evaluation of CAS outcomes and suggest that the development of such registries for other novel devices and treatments should be considered.
Our study has several limitations. As one of the largest national registries of carotid revascularization that includes all patients undergoing CAS at participating centers without exclusion or the need for patient informed consent, the CARE Registry has a population that is likely to be representative of the broader population of patients undergoing CAS in the United States. However, limited data exist to confirm this, and because it is a voluntary registry, the patient populations or treatment outcome reflected in the registry may differ from those seen in nonparticipating centers. In addition, despite the use of a hierarchical propensity score-adjusted model that accounted for a large number of clinical and procedural variables, we were not able to account completely for differences in mortality between groups. Further studies to evaluate the causes of these differences are warranted.
Conclusions
Patients undergoing CAS who participated in PMS studies had less baseline neurological disease and lower mortality compared with those CAS patients not participating in these studies. Results from PMS studies of CAS are unlikely to be representative of outcomes in true real-world practice. Further confirmation of these findings is needed. Large, inclusive clinical registries may be superior to company-sponsored PMS studies for conducting postapproval surveillance of newly approved devices. 
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CLINICAL PERSPECTIVE
Postmarketing surveillance studies (PMS) are commonly performed after the approval of cardiovascular devices and medications to evaluate the efficacy and safety of these therapies in real world practice, often at the request of the Food and Drug Administration. However, few studies have examined whether patient characteristics and outcomes of PMS studies are truly representative of those treated in routine clinical practice. In this study from the National Cardiovascular Database Registry-Carotid Artery Revascularization and Endarterectomy (NCDR CARE) registry, the authors compared clinical characteristics and outcomes of patients undergoing carotid artery stenting (CAS) enrolled in postmarketing studies to those not enrolled in such studies. PMS study participants had overall less severe neurological disease histories, better in-hospital outcomes, and lower long-term mortality rates compared to nonparticipants, even after propensity-score adjustment. The findings suggest that PMS studies of CAS include a healthier population of patients than those undergoing CAS in routine practice, and that extrapolating results from PMS studies of CAS to larger real world settings may not be appropriate. They also further confirm the importance of large inclusive disease registries with minimal exclusion criteria to properly evaluate the safety and efficacy of newly disseminated technologies in routine practice. Tables   Supplemental Table 1 
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